Study of promising novel biomarkers on cardio vascular diseases

Jalaiah M; Pavankalyan T; Maduri CH; Akhila Devi B; Honey B; Chiranjeevi K

doi:10.37022/jpmhs.v7i1.101

Authors

M.Jalaiah Department of Pharmacy, QIS College of Pharmacy, Vengamukka Palem, Ongole
T.Pavankalyan Department of Pharmacy, QIS College of Pharmacy, Vengamukka Palem, Ongole
CH Maduri Department of Pharmacy, QIS College of Pharmacy, Vengamukka Palem, Ongole
B Akhila Devi Department of Pharmacy, QIS College of Pharmacy, Vengamukka Palem, Ongole
B Honey Department of Pharmacy, QIS College of Pharmacy, Vengamukka Palem, Ongole
K Chiranjeevi Department of Pharmacy, QIS College of Pharmacy, Vengamukka Palem, Ongole

DOI:

https://doi.org/10.37022/jpmhs.v7i1.101

Keywords:

pathogenic traits, progression, indicators, and bioactive substances

Abstract

An excellent paper that provides a comprehensive analysis of biomarkers, which can disclose a variety of information about health or illness, such as the kind or extent of environmental exposure, genetic Vulnarability, genetic responses to exposures, indicators of preclinical or clinical illness, or indications of the treatment response. Indicators of disease trait , disease stage (preclinical or clinical), or illness rate are thus a basic approach to conceptualize biomarkers. A trait that can be objectively measured and evaluated is called a biomarker. as a gauge for biological activities that are pathogenic, healthy, or pharmaceutical responses to a treatment As a result, this paper examines the wealth of research on the function of bioactive compounds in a range of pathological processes associated with different

Downloads

Download data is not yet available.

References

Sipos B, Jirak P, Paar V, Rezar R, Mirna M, Kopp K, Hoppe UC, Berezin AE, Lichtenauer M. Promising novel biomarkers in cardiovascular diseases. Applied Sciences. 2021 Apr 19;11(8):3654.

Sun J, Axelsson J, Machowska A, Heimbürger O, Bárány P, Lindholm B, Lindström K, Stenvinkel P, Qureshi AR. Biomarkers of cardiovascular disease and mortality risk in patients with advanced CKD. Clinical Journal of the American Society of Nephrology. 2016 Jul 1;11(7):1163-72.

Sipos B, Jirak P, Paar V, Rezar R, Mirna M, Kopp K, Hoppe UC, Berezin AE, Lichtenauer M. Promising novel biomarkers in cardiovascular diseases. Applied Sciences. 2021 Apr 19;11(8):3654.

Li J, Cao T, Wei Y, Zhang N, Zhou Z, Wang Z, Li J, Zhang Y, Wang S, Wang P, Cheng N. A review of novel cardiac biomarkers in acute or chronic cardiovascular diseases: the role of soluble ST2 (sST2), lipoprotein-associated phospholipase A2 (Lp-PLA2), myeloperoxidase (MPO), and procalcitonin (PCT). Disease Markers. 2021 Aug 9;2021.

Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. The Lancet. 2010 Jan 9;375(9709):132-40.

Jacob R, Khan M. Cardiac biomarkers: what is and what can be. Indian journal of cardiovascular disease in women WINCARS. 2018 Dec;3(4):240.

Saheera S. Multifaceted role of cardiovascular biomarkers. Indian Heart Journal. 2023 Mar 1;75(2):91-7.

Dhingra R, Vasan RS. Biomarkers in cardiovascular disease: Statistical assessment and section on key novel heart failure biomarkers. Trends in cardiovascular medicine. 2017 Feb 1;27(2):123-33.

Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006 May 16;113(19):2335-62.

Fried LF, Shlipak MG, Crump C, Kronmal RA, Bleyer AJ, Gottdiener JS, Kuller LH, Newman AB. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. Journal of the American College of Cardiology. 2003 Apr 16;41(8):1364-72.

Kooman JP, Kotanko P, Schols AM, Shiels PG, Stenvinkel P. Chronic kidney disease and premature ageing. Nature Reviews Nephrology. 2014 Dec;10(12):732-42.

Levin A, Foley RN. Cardiovascular disease in chronic renal insufficiency. American journal of kidney diseases. 2000 Dec 1;36(6):S24-30.

Menon V, Gul A, Sarnak MJ. Cardiovascular risk factors in chronic kidney disease. Kidney international. 2005 Oct 1;68(4):1413-8.

Ross R. Atherosclerosis—an inflammatory disease. New England journal of medicine. 1999 Jan 14;340(2):115-26.

Zoccali C, Mallamaci F, Tripepi G. Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease. Nephrology Dialysis Transplantation. 2004 Aug 1;19(suppl_5):v67-72.

Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. Bmj. 2004 Jul 15;329(7458):168-9.

Solberg HE. International federation of clinical chemistry (IFCC), scientific committee, clinical section, expert panel on theory of reference values, and international committee for standardization in haematology (ICSH), standing committee on reference values. Approved recommendation (1986) on the theory of reference values. Part 1. The concept of reference values. Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie. 1987 May;25(5):337-42.

Lott JA, Mitchell LC, Moeschberger ML, Sutherland DE. Estimation of reference ranges: how many subjects are needed?. Clinical chemistry. 1992 May 1;38(5):648-50.

Morrow DA, Antman EM. Evaluation of high-sensitivity assays for cardiac troponin. Clinical chemistry. 2009 Jan 1;55(1):5-8.

Sunderman Jr FW. Current concepts of" normal values,"" reference values," and" discrimination values" in clinical chemistry. Clinical Chemistry. 1975 Dec 1;21(13):1873-7.